{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:21:22Z","timestamp":1767705682313},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The National Key Technologies R&D program for New Drugs","award":["2009ZX09503"],"award-info":[{"award-number":["2009ZX09503"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["30900634","30901462"],"award-info":[{"award-number":["30900634","30901462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.bbrc.2010.12.111","type":"journal-article","created":{"date-parts":[[2010,12,31]],"date-time":"2010-12-31T09:19:05Z","timestamp":1293787145000},"page":"31-36","source":"Crossref","is-referenced-by-count":11,"title":["Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR\/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1"],"prefix":"10.1016","volume":"405","author":[{"given":"Qing-Fang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue-Feng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu-Tse","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2010.12.111_b0005","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1182\/blood-2004-12-4704","article-title":"Regulation of survivin expression through Bcr\u2013Abl\/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells","volume":"107","author":"Carter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2010.12.111_b0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2008.95","article-title":"Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells","volume":"22","author":"Bonhoure","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2010.12.111_b0015","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1038\/sj.onc.1210587","article-title":"Sphingosine kinase-1 mediates BCR\/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells","volume":"26","author":"Li","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2010.12.111_b0020","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","article-title":"Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides","volume":"105","author":"Aichberger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2010.12.111_b0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","article-title":"Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR\u2013ABL \u2013 inhibition of P-glycoprotein function by 17-AAG","volume":"19","author":"Radujkovic","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2010.12.111_b0030","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2010.12.111_b0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2141.2008.07474.x","article-title":"In vitro anti-leukaemia activity of sphingosine kinase inhibitor","volume":"144","author":"Ricci","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2010.12.111_b0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.109.163337","article-title":"A novel sphingosine kinase inhibitor induces autophagy in tumor cells","volume":"333","author":"Beljanski","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2010.12.111_b0045","first-page":"92","article-title":"The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients","volume":"27","author":"van der Heijden","year":"2009","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bbrc.2010.12.111_b0050","first-page":"2961","article-title":"Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent","volume":"29","author":"Vaziri","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2010.12.111_b0055","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1182\/blood-2008-06-164582","article-title":"Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells","volume":"115","author":"Heaney","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2010.12.111_b0060","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-08-1953","article-title":"Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines","volume":"15","author":"Stein","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2010.12.111_b0065","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.2009.07875.x","article-title":"Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"147","author":"Vogl","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbrc.2010.12.111_b0070","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1080\/10428190902856790","article-title":"A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma \u2013 long-term results of a multicenter observation study","volume":"50","author":"Weigert","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2010.12.111_b0075","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/art.24864","article-title":"SIRT1 regulation of apoptosis of human chondrocytes","volume":"60","author":"Takayama","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbrc.2010.12.111_b0080","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr\u2013Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbrc.2010.12.111_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00062752-200207000-00007","article-title":"Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia","volume":"9","author":"Gorre","year":"2002","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bbrc.2010.12.111_b0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF03256446","article-title":"Anticipating clinical resistance to target-directed agents: the BCR\u2013ABL paradigm","volume":"10","author":"Azam","year":"2006","journal-title":"Mol. Diagn. Ther."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10023491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X10023491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T21:52:51Z","timestamp":1544046771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X10023491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0006291X10023491"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.12.111","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}